If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms, Decision Resources is offering an exclusive analyst call entitled Benign Prostatic Hyperplasia: How Will the Discontinuation of Ozarelix and Launches of PRX-302 and NX-1207 Impact the Novel Injectables Landscape for BPH? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Three recent events have altered the landscape of emerging injectable therapies for benign prostatic hyperplasia/male lower urinary tract symptoms. First, in response to disappointing Phase II data, development of AEterna Zentaris/Spectrum/Nippon Kayaku’s ozarelix was discontinued. Second, following the recently-announced results of the TRIUMPH clinical trial, Decision Resources now forecasts that Protox Therapeutics’ emerging agent PRX-302 will launch for benign prostatic hyperplasia/male lower urinary tract symptoms. Third, in the wake of a recently-published peer-reviewed article on Nymox’s emerging agent, NX-1207, this drug has been added to our forecast. In light of these events, as well as the current status of development programs for Allergan’s Botox, Decision Resources has also revised the expected launch date for Botox. This 15-minute analyst call, presented by Therapeutic Area Director Melissa Stolper, will answer the following questions:
Ms. Stolper will conduct a live Q & A session after the presentation. Registration Benign Prostatic Hyperplasia: How Will the Discontinuation of Ozarelix and Launches of PRX-302 and NX-1207 Impact the Novel Injectables Landscape for BPH? February 4, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||||
Melissa G. Stolper is a therapeutic area director in the Immune and Inflammatory group at Decision Resources. While at Decision Resources, Ms. Stolper’s work has focused on several disease areas, including respiratory, gastrointestinal, rheumatology, and genitourinary markets. Before joining the company, she worked as an associate consultant at ISO Healthcare Consulting, a boutique consulting firm in New York City servicing the pharmaceutical, biotechnology, and medical device industries. While at ISO, she collaborated on numerous strategic projects, particularly in the areas of franchise planning and R&D and market opportunity assessment. Ms. Stolper holds a B.A. in biology from Amherst College.
